
Kiersten V. Summers
Examiner (ID: 6714, Phone: (571)272-6542 , Office: P/3688 )
| Most Active Art Unit | 3688 |
| Art Unit(s) | 3626, 3682, 3688, 3621, 3687 |
| Total Applications | 352 |
| Issued Applications | 42 |
| Pending Applications | 73 |
| Abandoned Applications | 260 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17503444
[patent_doc_number] => 20220096546
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => Modified Cell Expansion and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/420066
[patent_app_country] => US
[patent_app_date] => 2020-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52397
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420066
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/420066 | Modified Cell Expansion and Uses Thereof | Jan 9, 2020 | Pending |
Array
(
[id] => 18315131
[patent_doc_number] => 11629200
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-18
[patent_title] => Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
[patent_app_type] => utility
[patent_app_number] => 16/733376
[patent_app_country] => US
[patent_app_date] => 2020-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 27
[patent_no_of_words] => 39498
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733376
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/733376 | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders | Jan 2, 2020 | Issued |
Array
(
[id] => 15802931
[patent_doc_number] => 20200124608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => PREDICTING CANCER PROGRESSION
[patent_app_type] => utility
[patent_app_number] => 16/730778
[patent_app_country] => US
[patent_app_date] => 2019-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9084
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16730778
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/730778 | Predicting cancer progression | Dec 29, 2019 | Issued |
Array
(
[id] => 16452613
[patent_doc_number] => 20200362039
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/728609
[patent_app_country] => US
[patent_app_date] => 2019-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91622
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728609
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/728609 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | Dec 26, 2019 | Abandoned |
Array
(
[id] => 17875560
[patent_doc_number] => 11447561
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => PD-L1 antibodies binding canine PD-L1
[patent_app_type] => utility
[patent_app_number] => 16/718729
[patent_app_country] => US
[patent_app_date] => 2019-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 28106
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718729
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/718729 | PD-L1 antibodies binding canine PD-L1 | Dec 17, 2019 | Issued |
Array
(
[id] => 16111703
[patent_doc_number] => 20200207874
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY
[patent_app_type] => utility
[patent_app_number] => 16/704781
[patent_app_country] => US
[patent_app_date] => 2019-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43911
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16704781
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/704781 | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery | Dec 4, 2019 | Issued |
Array
(
[id] => 15586459
[patent_doc_number] => 20200069764
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-05
[patent_title] => ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
[patent_app_type] => utility
[patent_app_number] => 16/688173
[patent_app_country] => US
[patent_app_date] => 2019-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50019
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16688173
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/688173 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | Nov 18, 2019 | Abandoned |
Array
(
[id] => 18428725
[patent_doc_number] => 11673935
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-13
[patent_title] => Car T-cells recognizing cancer-specific IL 13Ra2
[patent_app_type] => utility
[patent_app_number] => 16/675861
[patent_app_country] => US
[patent_app_date] => 2019-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 48
[patent_no_of_words] => 43610
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675861
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/675861 | Car T-cells recognizing cancer-specific IL 13Ra2 | Nov 5, 2019 | Issued |
Array
(
[id] => 15553515
[patent_doc_number] => 20200061169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => VACCINES WITH HIGHER CARBOHYDRATE ANTIGEN DENSITY AND NOVEL SAPONIN ADJUVANT
[patent_app_type] => utility
[patent_app_number] => 16/671395
[patent_app_country] => US
[patent_app_date] => 2019-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16671395
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/671395 | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant | Oct 31, 2019 | Issued |
Array
(
[id] => 15435511
[patent_doc_number] => 20200031939
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-30
[patent_title] => Antibodies Against Human NKG2D and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 16/655646
[patent_app_country] => US
[patent_app_date] => 2019-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655646
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/655646 | Antibodies Against Human NKG2D and Uses Thereof | Oct 16, 2019 | Abandoned |
Array
(
[id] => 17292262
[patent_doc_number] => 20210388101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME
[patent_app_type] => utility
[patent_app_number] => 17/285836
[patent_app_country] => US
[patent_app_date] => 2019-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12841
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285836
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/285836 | PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME | Oct 3, 2019 | Pending |
Array
(
[id] => 17292262
[patent_doc_number] => 20210388101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME
[patent_app_type] => utility
[patent_app_number] => 17/285836
[patent_app_country] => US
[patent_app_date] => 2019-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12841
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285836
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/285836 | PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME | Oct 3, 2019 | Pending |
Array
(
[id] => 15407817
[patent_doc_number] => 20200024230
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-23
[patent_title] => PGAM1 Inhibitors and Methods Related Thereto
[patent_app_type] => utility
[patent_app_number] => 16/590358
[patent_app_country] => US
[patent_app_date] => 2019-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16590358
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/590358 | PGAM1 Inhibitors and Methods Related Thereto | Sep 30, 2019 | Abandoned |
Array
(
[id] => 17198673
[patent_doc_number] => 20210338767
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => METHODS OF SELECTING TREATMENT FOR CXCR4-ASSOCIATED CANCER
[patent_app_type] => utility
[patent_app_number] => 17/279775
[patent_app_country] => US
[patent_app_date] => 2019-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279775
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279775 | METHODS OF SELECTING TREATMENT FOR CXCR4-ASSOCIATED CANCER | Sep 24, 2019 | Abandoned |
Array
(
[id] => 17214578
[patent_doc_number] => 20210347915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => METHODS OF REVERSING TICAGRELOR ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/278075
[patent_app_country] => US
[patent_app_date] => 2019-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23356
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/278075 | METHODS OF REVERSING TICAGRELOR ACTIVITY | Sep 19, 2019 | Pending |
Array
(
[id] => 17214578
[patent_doc_number] => 20210347915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => METHODS OF REVERSING TICAGRELOR ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/278075
[patent_app_country] => US
[patent_app_date] => 2019-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23356
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/278075 | METHODS OF REVERSING TICAGRELOR ACTIVITY | Sep 19, 2019 | Pending |
Array
(
[id] => 15324115
[patent_doc_number] => 20200002387
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME
[patent_app_type] => utility
[patent_app_number] => 16/568638
[patent_app_country] => US
[patent_app_date] => 2019-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568638
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/568638 | CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME | Sep 11, 2019 | Abandoned |
Array
(
[id] => 15209895
[patent_doc_number] => 20190367634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => ANTI-GPC3 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/546787
[patent_app_country] => US
[patent_app_date] => 2019-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16546787
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/546787 | Anti-GPC3 antibody | Aug 20, 2019 | Issued |
Array
(
[id] => 15209895
[patent_doc_number] => 20190367634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => ANTI-GPC3 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/546787
[patent_app_country] => US
[patent_app_date] => 2019-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16546787
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/546787 | Anti-GPC3 antibody | Aug 20, 2019 | Issued |
Array
(
[id] => 15209895
[patent_doc_number] => 20190367634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => ANTI-GPC3 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/546787
[patent_app_country] => US
[patent_app_date] => 2019-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16546787
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/546787 | Anti-GPC3 antibody | Aug 20, 2019 | Issued |